IP Library Granted Patent US 7,638,283
Granted Patent B2
US 7,638,283 · App. 11/130,566 · Granted Dec 29, 2009

Amyloid β protein (globular assembly and uses thereof)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,638,283
App. No.
11/130,566
Granted
Dec 29, 2009
Kind
B2
Abstract

The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid β peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

Claims (10)

1. A method for identifying compounds that block receptor binding of a soluble non-fibrillar amyloid β protein assembly, comprising:

(a) mixing a test compound with a cell culture media after formation of a soluble non-fibrillar amyloid β protein assembly comprising 3-12 amyloid β proteins, wherein the amyloid β proteins are the amyloid β 1-42 protein and having neurotoxic activity;

(b) contacting the mixture of 11(a) with B103 cells or other neuronal cells;

(c) adding a labeled reagent that can bind to the protein assembly of 11(a); and

(d) detecting the presence of the labeled reagent bound to the protein assembly.

2. A method for identifying compounds that block formation of a soluble non-fibrillar amyloid β protein assembly, comprising:

(a) mixing a test compound with a cell culture media before formation of a soluble non-fibrillar amyloid β protein assembly comprising 3-12 amyloid β proteins, wherein the amyloid β proteins are the amyloid β 1-42 protein and having neurotoxic activity;

(b) contacting the mixture of 12(a) with B103 cells or other neuronal cells;

(c) adding a labeled reagent that can bind to the protein assembly of 12(a);

(d) detecting the presence of the labeled reagent bound to the protein assembly, wherein test compounds exhibiting more inhibition of receptor binding of the protein assembly when the test compound is added before the formation of the protein assembly of 12(a), compared with addition of test compounds after formation, are compounds that block formation of the protein assembly.

Assignments (7)
CONFIRMATORY LICENSE Recorded Dec 26, 2021
From: NORTHWESTERN UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 058477/0487 →
CONFIRMATORY LICENSE Recorded Jul 8, 2008
From: NORTHWESTERN UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021206/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2008
From: KRAFFT, GRANT A.; KLEIN, WILLIAM L.; CHROMY, BRETT A.; LAMBERT, MARY P.; BARLOW, ANN
To: NORTHWESTERN UNIVERSITY
Reel/Frame 020423/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2008
From: WALS, PAT
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 020381/0728 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2007
From: FINCH, CALEB E.; MORGAN, TODD; ROZOVSKY, IRINA
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 020226/0941 →
SECURITY AGREEMENT Recorded Jul 30, 2007
From: ACUMEN PHARMACEUTICALS, INC.
To: VENTURE LENDING & LEASING IV, INC.; VENTURE LENDING & LEASING V, INC.
Reel/Frame 019658/0595 →
SECURITY AGREEMENT Recorded Jul 5, 2007
From: ACUMEN PHARMACEUTICALS, INC.
To: VENTURE LENDING & LEASING IV, INC.; VENTURE LENDING & LEASING V, INC.
Reel/Frame 019529/0857 →